- 3-Hydroxy-(3beta)-Lup-20(29)-en-28-oic acid
- 3-Hydroxylup-20(29)-en-28-oic acid
- 3beta-Hydroxy-20(29)-lupaene-28-oic acid
- 3beta-hydroxy-Lup-20(29)-en-28-oic acid
- Betulic acid
- Lup-20(29)-en-28-oic acid, 3beta -hydroxy-
IUPAC Name – (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-9-hydroxy-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-3a-carboxylic acid
Empirical Formula – C30H48O3
Molecular Weight – 456.71
Exact Mass – 456.36
Elemental Analysis – C, 78.90; H, 10.59; O, 10.51
- Anti-HIV Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Antineoplastic Agents, Phytogenic
- Prostaglandin Antagonists
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions.They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.
Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human.
Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
Compounds that inhibit the action of prostaglandins.